Search Results - listed+lpm+thalhammer-reyero+as+of+4%2f15%2f2015

7 Results

Sort By:

Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation

Local inflammation processes are crucially important in the host defense against pathogens and for successful immunization because proinflammatory cytokines are necessary for initiation and propagation of an immune response. However, normal inflammatory responses are eventually terminated by physiological termination mechanisms, thereby limiting the...

Published: 7/25/2024 | Inventor(s): Akio Ohta, Michail Sitkovsky

Keywords(s): 2IXXXX, 2JXXXX, CB3CXX, CB6XXX, Controlling, DC1XXX, IA3XXX, Inflammation, Listed LPM Thalhammer-Reyero as of 4/15/2015, Method, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Therapeutics, Application > Vaccines

Novel Multivalent Nanoparticle Vaccines

Current seasonal influenza vaccines are designed to elicit immunity to circulating strains of influenza each year. The targeted strains are selected based on predictions of which strains are likely to be predominant in the human population for a given year. This prediction must be made well ahead of the influenza season to allow time for vaccine production...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Hadi Yassine, Barney Graham

Keywords(s): ARRAY, Broader, DOMAINS, HEMAGGLUTININ, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, MOSAIC, Nanoparticulate, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Receptor-Binding, Receptor-bindingdomains, Spectrum, Vaccine

Category(s): Collaboration Sought > Licensing

Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof

An effective universal influenza vaccine would eliminate the uncertain and costly process of seasonal influenza vaccine development each year. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein...

Published: 7/25/2024 | Inventor(s): Jeffrey Boyington, Hadi Yassine, Peter Kwong, Masaru Kanekiyo, Barney Graham, John Mascola

Keywords(s): Broad, Development, ELICIT, HEMAGGLUTININ, IMMUNE, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, Modified, Nanoparticles, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RESPONSE, Stem

Category(s): Collaboration Sought > Licensing

Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...

Published: 7/25/2024 | Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola

Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine

The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization...

Published: 7/25/2024 | Inventor(s): Jason Gorman, Gilad Ofek, Marie Pancera, Mallika Sastry, Sanjay Srivatsan, Yongping Yang, Lei Chen, Cinque Soto, Tongqing Zhou, Barney Graham, Peter Kwong, Masaru Kanekiyo, Michael Joyce, Baoshan Zhang, Guillaume Stewart-Jones, Jeffrey Boyington, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason McLellan

Keywords(s): CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

N6, A Novel, Broad, Highly Potent HIV-specific Antibody

This is a new antibody coming out of NIAID’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment...

Published: 7/25/2024 | Inventor(s): Jinghe Huang, Byong Kang, John Mascola, Elise Ishida, Tongqing Zhou, Anqi Zheng, Peter Kwong, Mark Connors

Keywords(s): ANTIBODY, bNAb, Broad, Highly, HIV-soecific, HIV-Specific, Listed LPM Thalhammer-Reyero as of 4/15/2015, N6, Novel, Ootent, Post LPM Assignment Set 20150420, POTENT, Pre LPM working set 20150418

Category(s): Collaboration Sought > Collaboration

Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection

Ebola virus infection can lead to severe hemorrhagic fever, known as Ebola virus disease (EVD), which is often fatal. The Zaire species of Ebola virus (EBOV) was responsible for the largest Ebola outbreak in history, which occurred in 2014. Scientists at the NIAID Vaccine Research Center have developed a human monoclonal neutralizing antibody, mAb114...

Published: 7/25/2024 | Inventor(s): Antonio Lanzavecchia, Davide Corti, Barney Graham, Julie Ledgerwood, John Trefry, Daphne Stanley, Jean-Jacques Muyembe-Tamfun, Sabue Mulangu, Nancy Sullivan

Keywords(s): antibodies, Ebola, Ebolavirus, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, monoclonal, Neutralize, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, That, THEREOF, USES, virus

Category(s): Collaboration Sought > Licensing